DE102004027358A1 - Pyrimidinverbindungen und ihre Verwendung - Google Patents

Pyrimidinverbindungen und ihre Verwendung Download PDF

Info

Publication number
DE102004027358A1
DE102004027358A1 DE102004027358A DE102004027358A DE102004027358A1 DE 102004027358 A1 DE102004027358 A1 DE 102004027358A1 DE 102004027358 A DE102004027358 A DE 102004027358A DE 102004027358 A DE102004027358 A DE 102004027358A DE 102004027358 A1 DE102004027358 A1 DE 102004027358A1
Authority
DE
Germany
Prior art keywords
compounds
alkyl
butyl
group
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102004027358A
Other languages
German (de)
English (en)
Inventor
Hervé Geneste
Andreas Haupt
Wilfried Braje
Wilfried Lubisch
Gerd Steiner
Liliane Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Priority to DE102004027358A priority Critical patent/DE102004027358A1/de
Priority to PCT/EP2005/006000 priority patent/WO2005118558A2/de
Priority to JP2007513870A priority patent/JP5503845B2/ja
Priority to EP05750829.3A priority patent/EP1751116B1/de
Priority to EP11167864A priority patent/EP2361908A1/de
Priority to CA2567484A priority patent/CA2567484C/en
Priority to MXPA06013939A priority patent/MXPA06013939A/es
Priority to US11/628,658 priority patent/US7786105B2/en
Publication of DE102004027358A1 publication Critical patent/DE102004027358A1/de
Priority to US12/842,776 priority patent/US8268815B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE102004027358A 2004-06-04 2004-06-04 Pyrimidinverbindungen und ihre Verwendung Withdrawn DE102004027358A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE102004027358A DE102004027358A1 (de) 2004-06-04 2004-06-04 Pyrimidinverbindungen und ihre Verwendung
PCT/EP2005/006000 WO2005118558A2 (de) 2004-06-04 2005-06-03 Pyrimidinverbindungen und ihre verwendung
JP2007513870A JP5503845B2 (ja) 2004-06-04 2005-06-03 ピリミジン化合物およびそれの使用
EP05750829.3A EP1751116B1 (de) 2004-06-04 2005-06-03 Pyrimidinverbindungen und ihre Verwendung zur Behandlung von Erkrankungen des zentralen Nervensystems
EP11167864A EP2361908A1 (de) 2004-06-04 2005-06-03 Zur Behandlung von zentralnervösen Erkrankungen geeignete Pyrimidinverbindungen
CA2567484A CA2567484C (en) 2004-06-04 2005-06-03 Pyrimidine compounds and their use as modulators of the dopamine d3 receptor
MXPA06013939A MXPA06013939A (es) 2004-06-04 2005-06-03 Compuestos pirimidina y uso de los mismos.
US11/628,658 US7786105B2 (en) 2004-06-04 2005-06-03 Pyrimidine compounds and use thereof
US12/842,776 US8268815B2 (en) 2004-06-04 2010-07-23 Pyrimidine compounds and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004027358A DE102004027358A1 (de) 2004-06-04 2004-06-04 Pyrimidinverbindungen und ihre Verwendung

Publications (1)

Publication Number Publication Date
DE102004027358A1 true DE102004027358A1 (de) 2005-12-29

Family

ID=35134083

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004027358A Withdrawn DE102004027358A1 (de) 2004-06-04 2004-06-04 Pyrimidinverbindungen und ihre Verwendung

Country Status (7)

Country Link
US (2) US7786105B2 (cg-RX-API-DMAC7.html)
EP (2) EP2361908A1 (cg-RX-API-DMAC7.html)
JP (1) JP5503845B2 (cg-RX-API-DMAC7.html)
CA (1) CA2567484C (cg-RX-API-DMAC7.html)
DE (1) DE102004027358A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06013939A (cg-RX-API-DMAC7.html)
WO (1) WO2005118558A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259382A1 (de) * 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
PA8802101A1 (es) 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR095264A1 (es) 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62257158A (ja) 1986-04-30 1987-11-09 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
DE3800386A1 (de) 1988-01-09 1989-07-20 Bayer Ag Verfahren zur herstellung von benzothiazepinon-derivaten
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
DE4425145A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
DE19735410A1 (de) 1997-08-14 1999-02-18 Basf Ag 2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat
HUP0100926A3 (en) 1998-02-26 2003-03-28 Neurogen Corp Branford Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
DE19922443A1 (de) 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
CZ20022603A3 (cs) * 1999-12-30 2002-10-16 H. Lundbeck A/S 4-fenyl-1-piperazinylové deriváty
SK1092003A3 (en) * 2000-06-29 2003-05-02 Lundbeck & Co As H Indole derivatives useful for the treatment of CNS disorders
DE10304870A1 (de) 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung

Also Published As

Publication number Publication date
US7786105B2 (en) 2010-08-31
EP2361908A1 (de) 2011-08-31
MXPA06013939A (es) 2007-08-14
JP5503845B2 (ja) 2014-05-28
CA2567484C (en) 2012-10-30
WO2005118558A3 (de) 2006-02-09
US20080161322A1 (en) 2008-07-03
JP2008501662A (ja) 2008-01-24
WO2005118558A2 (de) 2005-12-15
CA2567484A1 (en) 2005-12-15
EP1751116B1 (de) 2013-07-31
US20110118232A1 (en) 2011-05-19
EP1751116A2 (de) 2007-02-14
US8268815B2 (en) 2012-09-18

Similar Documents

Publication Publication Date Title
WO2005056546A1 (de) Ketolactam-verbindungen und ihre verwendung
EP1144405B1 (de) Triazolverbindungen mit dopamin-d3-rezeptoraffinität
WO2004080981A1 (de) Pyrimidin-2-on-verbindungen und ihre verwendung als dopamin-d3-rezeptorliganden
US8334289B2 (en) Pyridin-2-one compounds and their use as modulators of the dopamine D3 receptor
EP1828146B1 (de) Substituierte n-heterocyclische verbindungen und ihre verwendung als dopamin d3 rezeptorliganden
US8268815B2 (en) Pyrimidine compounds and use thereof
US20040259882A1 (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
KR20100094491A (ko) 도파민 ｄ3 수용체의 조절에 반응하는 장애의 치료를 위한 １，２，４－트리아진－３，５－디온 화합물
EP1594861B1 (de) Triazolverbindungen und ihre therapeutische verwendung
DE602004000158T2 (de) Triazole für die Behandlung von auf die Modulation des Dopamin D3 Rezeptors ansprechende Krankheiten
EP2203426B1 (en) Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor

Legal Events

Date Code Title Description
R005 Application deemed withdrawn due to failure to request examination

Effective date: 20110606